Geninus Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
389030
- Share Price
-
$0.94
- (As of Thursday Closing)
Geninus General Information
Description
Geninus Inc provides clinical genome analysis solutions for precision medicine clinics.
Contact Information
Website
geninustx.comCorporate Office
- 70,Jeongui-ro
- 4th-5thFloor(Munjeong-dong,KDU Tower)x
- Songpa, Songpa-gu
- South Korea
Corporate Office
- 70,Jeongui-ro
- 4th-5thFloor(Munjeong-dong,KDU Tower)x
- Songpa, Songpa-gu
- South Korea
Geninus Stock Performance
As of 19-Nov-2026, Geninus’s stock price is $0.94. Its current market cap is $37.2M with 39.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.94 | $0.98 | $0.74 - $4.34 | $37.2M | 39.4M | 474K | -$0.41 |
Geninus Financials Summary
As of 30-Jun-2026, Geninus has a trailing 12-month revenue of $7.77M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 49,747 | 77,471 | 26,598 | 51,763 |
| Revenue | 7,771 | 7,366 | 4,731 | 5,329 |
| EBITDA | (11,626) | (9,703) | (7,184) | (6,101) |
| Net Income | (14,026) | (12,208) | (8,995) | (7,407) |
| Total Assets | 35,167 | 27,326 | 22,464 | 31,448 |
| Total Debt | 4,975 | 6,341 | 4,144 | 1,383 |
Geninus Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Geninus Patents
Geninus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026164346-A1 | Method for generating a cell type annotation image, image processing device, and analysis device | Pending | 31-Jan-2025 | ||
| WO-2026146685-A1 | Composition for diagnosing prostate cancer using methylation level of cpg regions and use thereof | Pending | 02-Jan-2025 | ||
| JP-2025076278-A | Colorectal cancer diagnostic composition using cpg region methylation levels, and uses thereof | Active | 31-Oct-2023 | ||
| WO-2025095485-A1 | Composition for diagnosing colorectal cancer using methylation level of cpg site and use thereof | Inactive | 31-Oct-2023 | ||
| US-20260245654-A1 | Method and device for estimating binding between peptide and t cell receptor | Pending | 24-Jun-2022 | G16B15/30 |
Geninus Signals
Geninus Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Geninus ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Geninus FAQs
-
When was Geninus founded?
Geninus was founded in 2017.
-
Where is Geninus headquartered?
Geninus is headquartered in Songpa, South Korea.
-
What is the size of Geninus?
Geninus has 63 total employees.
-
What industry is Geninus in?
Geninus’s primary industry is Laboratory Services (Healthcare).
-
Is Geninus a private or public company?
Geninus is a Public company.
-
What is Geninus’s stock symbol?
The ticker symbol for Geninus is 389030.
-
What is the current stock price of Geninus?
As of 19-Nov-2026 the stock price of Geninus is $0.94.
-
What is the current market cap of Geninus?
The current market capitalization of Geninus is $37.2M.
-
What is Geninus’s current revenue?
The trailing twelve month revenue for Geninus is $7.77M.
-
What is Geninus’s annual earnings per share (EPS)?
Geninus’s EPS for 12 months was -$0.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process